EV101

**EV101** is a preclinical cancer immunotherapy candidate from **EV Therapeutics** built on the company's modified tumor extracellular vesicle platform. It is described as a first-in-class **extracellular vesicle based therapy** derived from modified tumor extracellular vesicles and has shown preclinical activity in solid tumor and advanced metastatic animal models, both as monotherapy and in combination with immune checkpoint inhibitors. Publicly available information indicates development focus in oncology, particularly advanced-stage colorectal cancer, but the precise molecular payload, formulation details, and definitive human dosing route have not been publicly disclosed.

Other names

EV-101EV101EV 101